Stockwatch
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Stockwatch: The Pandemic’s Effects On Big Pharma – A Year In
Depending on the therapeutic area, a fall in pharmaceutical sales was an obvious effect of the pandemic, although lower selling and marketing expenses and fewer non-COVID-19 infections were minor positives.
Stockwatch: Oncology Dynamics Underscore Roche And AstraZeneca’s Contrasting Fortunes
Roche’s full-year 2020 results suggested that it had seen better days. By contrast, the turnaround narrative at AstraZeneca suggested that its worst days were behind it.
Stockwatch: Lilly’s Fourth Quarter − Pandemic Benefits And Challenges
Lilly’s fourth-quarter results included windfalls, not just from the pandemic but from seasonal wholesaler buying patterns that were intensified by the pandemic and raise a high bar for subsequent quarters.
Stockwatch: J&J And Novartis Fire Opening Salvos Of Earnings Season
J&J’s bullish outlook for 2021, robust fourth quarter and frequent guidance revisions in uncertain times contrasted with Novartis’s reticence.
Stockwatch: The Mixed History Of Biotech Company Separations
The path of spin-offs from loss-making biotech companies with weak investment propositions seems clouded with examples that often resulted in an appointment with the liquidator.
Stockwatch: Subdued Virtual J.P. Morgan Conference Prefaces Full-Year Earnings Season
Deals announced by Sanofi and Novartis at this year’s virtual J.P. Morgan Healthcare Conference and a smattering of full-year revenue preannouncements did not mark a bumper start to the year.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.